The updated release reads: IASO RECEIVES NMPA ACCEPTANCE OF ITS FIRST INDICATION IND APPLICATION FOR CT120, A FULLY HUMAN CD19/CD22 DUAL-TARGETING CAR-T THERAPY IASO Biotherapeutics (IASO Bio), a ...

CT120 is the first fully human dual-targeted CAR-T cell therapy approved to enter the clinical stage. The clinical trial of CT120 in patients with relapsed/refractory B-cell acute lymphoblastic ...